Brief: Diffusion Pharma Announces Strategic Review Process To Evaluate Value-Enhancing Alternatives Including Opportunities To Better Leverage TSC

CervoMed

25/10/2022 12:23

Oct 25 (Reuters) - Diffusion Pharmaceuticals Inc
 DFFN.O :
    * DIFFUSION PHARMACEUTICALS ANNOUNCES STRATEGIC REVIEW
PROCESS TO
EVALUATE VALUE-ENHANCING ALTERNATIVES INCLUDING OPPORTUNITIES TO
BETTER LEVERAGE TSC
    * DIFFUSION PHARMACEUTICALS- TO EXPAND EVALUATION TO OPTIONS
INCLUDING JOINT VENTURE, LICENSING, SALE, DIVESTITURE OF SOME OF
CO'S PROPRIETARY TECHNOLOGIES
    * DIFFUSION PHARMACEUTICALS INC- BOARD TO EXPAND ITS
EVALUATION TO
A BROADER RANGE OF OPTIONS ALSO INCLUDING A SALE OF COMPANY

Source text for Eikon:  ID:nGNXGwCWL 
Further company coverage:  DFFN.O 
 ((Reuters.Briefs@thomsonreuters.com;;))